6 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 4 Phase 1, 4 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Her2-negative Metastatic Breast Cancer: new trials by email Literature Review of Her2-negative Metastatic Breast Cancer trials Research Report on Her2-negative Metastatic Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MTX-531-001 Phase 1 Study in Advanced Solid Tumors MTX-531 - Solid Tumors (Phase 1), HNSCC | Phase 1 | Not yet recruiting | MEKanistic Therapeutics, Inc. | 71 | 2026-10-20 | 2026-10-15 |
| Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d. - Her2-negative Metastatic Breast Cancer, Vinorelbine | Phase 2 | Unknown | Wang Jiayu | 30 | 2024-11-01 | 2024-10-23 |
| Adaptive Therapy for Post-Second-Line Advanced Breast Cancer Gemcitabine, Vinorelbine, or Eribulin - HER2-negative Metastatic Breast Cancer | Phase 2 | Completed | Sun Yat-sen University | 10 | 2024-08-04 | 2025-06-10 |
| Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant - Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer | Phase 4 | Recruiting | Prof. Wolfgang Janni | 300 | 2022-04-27 | 2025-05-16 |
| A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer DAN-222, Niraparib - HER2-negative Metastatic Breast Cancer | Phase 1 | Completed | Dantari, Inc. | 30 | 2022-02-02 | 2023-12-13 |
| Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer Chemotherapy monitoring by circulating tumor DNA analysis - HER2-negative Metastatic Breast Cancer | Phase 2 | Terminated | Institut Curie | 160 | 2021-04-21 | 2025-06-22 |
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Durvalumab, Eribulin - HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer | Phase 1 | Completed | Amy Tiersten | 9 | 2018-05-17 | 2020-08-05 |
| Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer Atezolizumab, Carboplatin, Docetaxel - HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer | Phase 1 | Completed | Hoffmann-La Roche | 98 | 2015-12-31 | 2020-02-05 |
| DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib - HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells | Phase 3 | Completed | Prof. Wolfgang Janni | 105 | 2012-02-01 | 2024-06-04 |
| Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer Vinorebine, Everolimus, Vinorelbine - Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 139 | 2012-01-01 | 2017-08-09 |
Breast Neoplasms (5) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Neoplastic Cells, Circulating (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (6) · Neoplasms by Site (6) · Breast Diseases (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adnexal Diseases (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1)
Vinorelbine (3) · eribulin (2) · Ado-Trastuzumab Emtansine (1) · Aromatase Inhibitors (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Drug Therapy (1) · Everolimus (1) · Fulvestrant (1) · Gemcitabine (1) · Lapatinib (1) · Trastuzumab (1) · abemaciclib (1)
Prof. Wolfgang Janni (2) · AIO-Studien-gGmbH (1) · Amy Tiersten (1) · Dantari, Inc. (1) · Hoffmann-La Roche (1) · Institut Curie (1) · MEKanistic Therapeutics, Inc. (1) · Sun Yat-sen University (1) · Wang Jiayu (1)
United States (4) · Germany (3) · China (1) · France (1) · Switzerland (1)
Amy Tiersten, MD (1) · Brigitte Rack, Prof. Dr. (1) · Tanja Fehm, MD, PhD (1) · Wolfgang Janni, MD, PhD (1) · Zhongyu Yuan, M.D. (1)
2015 (1)